Pharmacokinetically guided 5-fluorouracil dosing reduces severe toxicity and improves response rates in colorectal cancer
Tailored dosing of 5-fluorouracil improves safety for colorectal cancer
This systematic review and meta-analysis of 809 patients found that pharmacokinetically guided 5-fluorouracil dosing significantly reduced s…
Tailoring 5-fluorouracil doses based on how a patient's body processes the drug can lower severe side effects and improve treatment response…
Impact of Lifestyle and Nursing Interventions on Quality of Life in Gynecologic Cancers
Nursing and lifestyle support improve quality of life for ovarian cancer
A meta-analysis of 915 patients indicates that lifestyle and nursing interventions significantly improve quality of life specifically in ova…
Specialized nursing and lifestyle programs can significantly improve the quality of life for women living with ovarian cancer.
Endoscopic techniques like ESD and EMR offer distinct advantages for early colon cancer management
Different Endoscopic Techniques Offer Different Benefits for Early Colon Cancer
This narrative review evaluates endoscopic diagnosis and treatment methods for early colon cancer, specifically EMR, ESD, and EFTR. The auth…
Choosing the right endoscopic technique for early colon cancer depends on the size and risk of the lesion to balance safety and accurate sta…
AI-enabled D-dimeromics may identify ultra-high-risk breast cancer phenotypes for individualized treatment
AI and D-dimer may spot high-risk breast cancer
This narrative review explores the concept of AI-enabled D-dimeromics, combining D-dimer with haemostatic, inflammatory, molecular, radiolog…
Combining D-dimer with AI could reveal which breast cancers are most aggressive, but evidence is early.
FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
FDA approves new drug Bavencio for rare skin cancer
The FDA approved Bavencio (avelumab) for adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma. This PD-L1 …
The FDA has approved Bavencio (avelumab) for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer. It is the first therapy ap…
FDA Approves Unloxcyt (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma
FDA approves new immunotherapy drug Unloxcyt for advanced skin cancer
The FDA has approved Unloxcyt (cosibelimab-ipdl) for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are no…
The FDA approved Unloxcyt for adults with a type of advanced skin cancer called cutaneous squamous cell carcinoma. It is for patients who ca…
FDA Approves Imjudo (tremelimumab) for Unresectable Hepatocellular Carcinoma and Metastatic NSCLC
FDA approves new drug Imjudo for liver and lung cancers.
The FDA approved Imjudo (tremelimumab) in combination with durvalumab for unresectable hepatocellular carcinoma, and in combination with dur…
The FDA has approved Imjudo (tremelimumab) for two types of cancer: liver cancer that cannot be removed by surgery, and a certain type of ad…
FDA Approves Penpulimab-kcqx for Non-Keratinizing Nasopharyngeal Carcinoma
FDA approves new drug Penpulimab-kcqx for a type of nasopharyngeal cancer.
The FDA approved penpulimab-kcqx (a PD-1-blocking antibody) for two indications: in combination with cisplatin or carboplatin and gemcitabin…
The FDA has approved Penpulimab-kcqx for treating non-keratinizing nasopharyngeal carcinoma, a rare head and neck cancer. It can be used as …
FDA Approves Loqtorzi (toripalimab-tpzi) for Nasopharyngeal Carcinoma
FDA approves new drug Loqtorzi for a rare head and neck cancer
The FDA approved toripalimab-tpzi (Loqtorzi) for two indications: in combination with cisplatin and gemcitabine for first-line treatment of …
The FDA has approved Loqtorzi for nasopharyngeal carcinoma, a rare cancer of the throat. It can be used as a first treatment with chemothera…
Durvalumab plus tremelimumab shows no significant overall survival benefit compared to durvalumab alone
Adding tremelimumab to durvalumab does not improve lung cancer survival
This meta-analysis of 2726 patients with metastatic non-small cell lung cancer found no significant overall survival benefit for durvalumab …
Combining two specific immunotherapies for metastatic lung cancer does not improve survival but significantly increases the risk of severe s…
Approximately 61% of cancer patients resume anticancer treatment after unplanned ICU admission
Most cancer patients do not resume treatment after ICU stay
This meta-analysis of 3551 patients with solid tumors or hematological malignancies found that 61% of patients resumed any anticancer treatm…
Only about 60% of cancer patients resume any treatment after an unplanned ICU stay, highlighting a critical gap in care after a medical cris…
Ketone Supplementation Improves Metabolic and Hormonal Profiles in PCOS
Ketone supplements may improve metabolic health in women with PCOS
Meta-analysis finds ketone supplementation significantly reduces BMI, glucose, insulin, and androgens while increasing FSH and estrogen in P…
New data suggests ketone supplements can lower insulin, androgens, and BMI for women managing Polycystic ovary syndrome.